Skip to content
About
Company Overview
Our Investors
Our Team
Our Approach
Treg Platform
Off-the-shelf Allo
Scalable Manufacturing
Pipeline & Programs
Our Pipeline
GNTI-122 – T1D (POLARIS)
GNTI-148 – T1D
GNTI-932 – IBD
GNTI-350 – B/T cell-driven AID
GNTI-823 – Acute Inflammatory
News
Genti in the News
Publications
Conference Presentations
Contact
Locations
Careers
Toggle navigation
About
Company Overview
Our Investors
Our Team
Our Approach
Treg Platform
Off-the-shelf Allo
Scalable Manufacturing
Pipeline & Programs
Our Pipeline
GNTI-122 – T1D (POLARIS)
GNTI-148 – T1D
GNTI-932 – IBD
GNTI-350 – B/T cell-driven AID
GNTI-823 – Acute Inflammatory
News
Genti in the News
Publications
Conference Presentations
Contact
Locations
Careers
Genti Publication
May 11, 2024
Stable Expression of FOXP3 and Core Tolerogenic Genes by Engineered Human Tregs
Click here to download PDF
‹ Back to Publications
Toggle navigation
Toggle navigation